The CANVAS trial was supposed to provide definitive cardiovascular safety data for Janssen’s Invokana (canagliflozin) in type 2 diabetes – and while it has succeeded in this regard ...
The analysis pooled individual participant data from the CANVAS Program and CREDENCE trial and assessed efficacy and safety ...
The analysis pooled individual participant data from the CANVAS Program and CREDENCE trial and assessed efficacy and safety according to baseline age. Among the 14,543 participants, 7,927 (54.5% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback